Suppressive antibiotic treatment (SAT) in the era of MDRO infections: a narrative review.

IF 3.8 2区 医学 Q1 INFECTIOUS DISEASES Expert Review of Anti-infective Therapy Pub Date : 2025-05-01 Epub Date: 2025-03-04 DOI:10.1080/14787210.2025.2473077
Valentina Fornari, Guido Accardo, Tommaso Lupia, Francesco Giuseppe De Rosa, Silvia Corcione
{"title":"Suppressive antibiotic treatment (SAT) in the era of MDRO infections: a narrative review.","authors":"Valentina Fornari, Guido Accardo, Tommaso Lupia, Francesco Giuseppe De Rosa, Silvia Corcione","doi":"10.1080/14787210.2025.2473077","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Antibiotics were originally developed to treat acute bacterial infections, and research studies focus their efforts on safety and efficacy in the short term; however, prolonged course of antibiotics has been documented in multiple clinical settings. The aim of this narrative review is to provide a new perspective on SAT and to discuss new therapeuticpossibilities.</p><p><strong>Areas covered: </strong>We discuss new clinical scenarios in which SAT could be considered. We provided a broad discussion about long-acting agents and new or repurposed oral agents as well as the use of OPAT with elastomeric pumps and an overview of the pipeline of new antifungals. Limitations of SAT are presented in this review and especially patients' adherence issues, possible spread of MDROs, possible rising of the incidence of <i>Clostridioides difficile</i> infections, drug-to-drug interactions and drug-related problems, cost-effectiveness evaluation issues.</p><p><strong>Expert opinion: </strong>Many research gaps are evident and further studies are needed. Above all, the efficacy and safety of SAT in the different clinical scenarios. Discovery of new molecules against MDROs and ongoing research on PK/PD variables as well as a better understanding of the relationship between SAT and the emergence of resistance could improve SAT usage and reduce the impact of DRPs.</p>","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"291-303"},"PeriodicalIF":3.8000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anti-infective Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14787210.2025.2473077","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/4 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Antibiotics were originally developed to treat acute bacterial infections, and research studies focus their efforts on safety and efficacy in the short term; however, prolonged course of antibiotics has been documented in multiple clinical settings. The aim of this narrative review is to provide a new perspective on SAT and to discuss new therapeuticpossibilities.

Areas covered: We discuss new clinical scenarios in which SAT could be considered. We provided a broad discussion about long-acting agents and new or repurposed oral agents as well as the use of OPAT with elastomeric pumps and an overview of the pipeline of new antifungals. Limitations of SAT are presented in this review and especially patients' adherence issues, possible spread of MDROs, possible rising of the incidence of Clostridioides difficile infections, drug-to-drug interactions and drug-related problems, cost-effectiveness evaluation issues.

Expert opinion: Many research gaps are evident and further studies are needed. Above all, the efficacy and safety of SAT in the different clinical scenarios. Discovery of new molecules against MDROs and ongoing research on PK/PD variables as well as a better understanding of the relationship between SAT and the emergence of resistance could improve SAT usage and reduce the impact of DRPs.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
MDRO感染时代的抑制性抗生素治疗(SAT):叙述性回顾。
简介:抗生素最初是为了治疗急性细菌感染而开发的,研究的重点是短期的安全性和有效性;然而,延长疗程的抗生素已被记录在多个临床设置。这篇叙述性综述的目的是为SAT提供一个新的视角,并讨论新的治疗可能性。涉及领域:我们讨论了可以考虑SAT的新临床场景。我们提供了关于长效药物和新的或重新用途的口服药物的广泛讨论,以及OPAT与弹性体泵的使用,并概述了新的抗真菌药物的管道。本综述提出了SAT的局限性,特别是患者的依从性问题、耐多药耐药性的可能传播、艰难梭菌感染发生率的可能上升、药物间相互作用和药物相关问题、成本-效果评估问题。专家意见:许多研究差距很明显,需要进一步研究。最重要的是,SAT在不同临床情况下的有效性和安全性。抗mdro的新分子的发现和对PK/PD变量的持续研究,以及对SAT与耐药性之间关系的更好理解,可以提高SAT的使用,减少DRPs的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.20
自引率
0.00%
发文量
66
审稿时长
4-8 weeks
期刊介绍: Expert Review of Anti-Infective Therapy (ISSN 1478-7210) provides expert reviews on therapeutics and diagnostics in the treatment of infectious disease. Coverage includes antibiotics, drug resistance, drug therapy, infectious disease medicine, antibacterial, antimicrobial, antifungal and antiviral approaches, and diagnostic tests.
期刊最新文献
Why do we urgently need a new treatment for cerebral aspergillosis? Polypharmacy in infectious diseases care: mitigating the risk of complications. Effectiveness of bundles to prevent surgical site infections in cranial neurosurgery: systematic review, meta-analysis, and GRADE evaluation. The effect of combination antibiotic therapy on mortality in patients with sepsis or septic shock due to Pseudomonas aeruginosa bloodstream infections: a systematic review. Post-tuberculosis lung disease and pulmonary aspergillosis management: challenges and considerations.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1